Active Ingredient(s): Eptifibatide
FDA Approved: * May 18, 1998
Pharm Company: * SCHERING
Category: Intravenous (IV) Therapy

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Integrilin Overview

Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein (P22827) found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The ...

Read more Integrilin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Integrilin Forums: RSS Feed


heart ## The name of the medication being asked about is actually Integrilin, it is an antiplatelet agent that's used to help prevent blood clotting. You can learn more Integrilin details here. Side effects may include nausea, hypotension, increased risk of bleeding and heart failure. Are there any other questions or comments?


Possible Dosages for this and Related Drugs:

  • Injection: 0.75mg/ml, 2mg/ml, 75mg/100ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Integrilin: (2 results)

Sorted by National Drug Code
  • 0085-1136 Integrilin .75 mg/ml Intravenous Injection, Solution by Merck Sharp & Dohme Corp.
  • 0085-1177 Integrilin 2 mg/ml Intravenous Injection, Solution by Merck Sharp & Dohme Corp.

Other drugs which contain Eptifibatide or a similar ingredient: (1 result)

Related Integrilin Topics:

miocardial infarction...